Trial Profile
Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients With Different Forms of Refractory Uveitis Acronym: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 28 Feb 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Corticosteroids; Immunosuppressants
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms ADUR trial
- 16 May 2014 New trial record